<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033795</url>
  </required_header>
  <id_info>
    <org_study_id>VALORE</org_study_id>
    <nct_id>NCT05033795</nct_id>
  </id_info>
  <brief_title>Metabolomic Evaluation of the Impact of Acqua Rocchetta on the Skin of Healthy Patients.</brief_title>
  <official_title>Metabolomic Evaluation of the Impact of Rocchetta Water on the Skin of Healthy Patients Through the Innovative Method of Artificial Intelligence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of changes in skin metabolism after one month of intake of Acqua Rocchetta (water&#xD;
      A) vs bicarbonate-calcic mediomineral water (water B) (reprogramming effect on skin&#xD;
      metabolism); Evaluation of urinary profiles after intake of Acqua Rocchetta (water A) vs&#xD;
      bicarbonate-calcic mediomineral water (water B) and possible relation with skin metabolites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, interventional, randomized controlled clinical trial conducted in&#xD;
      healthy volunteers, in a double blind (subject and investigator).&#xD;
&#xD;
      The study will include age-matched female subjects who blindly take water A or water B, both&#xD;
      marketed as food and not supplements, therefore evaluated annually by the relevant bodies&#xD;
      (ASL, NAS and the Central Inspectorate for quality protection. and the repression of fraud on&#xD;
      agri-food products (Icqrf)).&#xD;
&#xD;
      Women between 30 and 50 years old will be chosen who have a skin aging pattern very different&#xD;
      from the male sex and governed by the oscillations of the menstrual cycle. A positive result&#xD;
      on this population would be of crucial importance in terms of nutriceuticals and&#xD;
      generalizability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipidomics</measure>
    <time_frame>three months</time_frame>
    <description>Different concentration in cutaneous lipids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinomics</measure>
    <time_frame>three months</time_frame>
    <description>quantfication of different urinary metabolites</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Skin</condition>
  <arm_group>
    <arm_group_label>Water A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 L of water A per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 L of water B per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water A</intervention_name>
    <description>2 L of water A per day</description>
    <arm_group_label>Water A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water B</intervention_name>
    <description>2 L of water B per day</description>
    <arm_group_label>Water B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy female subjects&#xD;
&#xD;
          -  in good health without disease with an ICD code in compliance with the World Health&#xD;
             Organisation definition (a state of complete physical, mental and social well-being&#xD;
             and not merely the absence of disease or infirmity.&quot; )&#xD;
&#xD;
          -  abstemious&#xD;
&#xD;
          -  individuals who agree to sign an informed consent form&#xD;
&#xD;
          -  individuals who follow an omnivorous diet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects outside the age range considered&#xD;
&#xD;
          -  smokers and/or those with chronic or acute diseases coded by the ICD-10 system&#xD;
&#xD;
          -  persons who do not consent to sign the informed consent form&#xD;
&#xD;
          -  subjects who follow diets that are not omnivorous or with fattening / slimming&#xD;
             purposes&#xD;
&#xD;
          -  subjects undergoing hormonal or contraceptive hormonal therapies or in general drugs&#xD;
             that may alter the hydroelectric balance&#xD;
&#xD;
          -  persons with significant alterations in the menstrual cycle (amenorrhoea or&#xD;
             dysmenorrhoea).&#xD;
&#xD;
          -  use of alcohol.&#xD;
&#xD;
          -  pregnancy (verified by self-declaration) and/or breastfeeding&#xD;
&#xD;
          -  allergy to the components of Leukopor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Pigatto, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCSS Istituto Ortopedico Galeazzi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Pigatto, Prof</last_name>
    <phone>0266214761</phone>
    <email>paolo.pigatto@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCSS Istituto Ortopedico Galeazzi</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pigatto, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

